A single infusion of an experimental CRISPR-Cas9 therapy was reported to safely lower LDL cholesterol by 52.5% and triglycerides by 47.8%, as measured 12 months after treatment. What if one infusion could keep cholesterol down for a year? An experimental gene-editing treatment called CTX310 has shown early promise in people whose cholesterol and other blood [...]